Disclosed is a pharmaceutical composition for modulating immunity, which comprises a benzimidazole, represented by the following general formula (I), a 3H tautomer, an optically active enantiomer or a pharmaceutically acceptable acid-addition salt thereof wherein, R represents an alkyl group having 1 to 5 carbon atoms, a hydroxyphenyl group or a methoxyphenyl group. This pharmaceutical composition is useful for treating cytokine-related diseases such as rheumatism, inflammation and allergy:

Claims

6 · 1 independent · depth 3

6 granted claims

›1.independentA method for modulating immunity comprising the step of administering, to a patient, a benzimidazole represented by the following general formula (I),…+5

Classifications

3 codes

IPC · International Patent Classification

Section A — Human necessities

A61K3/150

USPC · US Patent Classification

514/252.2514/252.1

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

Pendency

1.6 y

582 days filing → grant

Office actions

non-final + final

Responses

1 RCE

Examiner

Dwayne C. Jones

art unit —

Law firm

Law firm · Log in to unlock

Citations: 2 back · 0 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.